| 罗格列酮对2型糖尿病患者血脂水平和血浆PAI-1活性的影响 |
| |
| 引用本文： | 胡桂芳,武革,杨露. 罗格列酮对2型糖尿病患者血脂水平和血浆PAI-1活性的影响[J]. 湛江医学院学报, 2008, 26(3) |
| |
| 作者姓名： | 胡桂芳 武革 杨露 |
| |
| 作者单位： | 广东医学院附属医院,广东湛江,524001;浙江省杭州市第二人民医院,浙江杭州,310015 |
| |
| 摘 要： | 目的观察罗格列酮对2型糖尿病患者血脂水平和血浆纤溶酶原激活物抑制剂1(PAI-1)活性的影响。方法60例2型糖尿病患者随机分为常规治疗组和罗格列酮治疗组,每组30例,另选择20例健康体检者作为正常对照组。常规治疗组和罗格列酮治疗组分别于治疗前和治疗后12周检测空腹血糖(FPG)、血脂水平,采用发光底物法测定全部观察对象的PAI-1的活性。结果治疗12周后罗格列酮治疗组的血清甘油三酯(TG)下降、高密度脂蛋白胆固醇(HDL-C)升高,血浆PAI-1活性明显降低,差异有统计学意义(P<0.05)。结论罗格列酮可改善糖尿病患者的代谢紊乱,减少血浆PAI-1的表达,有助于改善或延缓糖尿病合并动脉粥样硬化的发生。
|
| 关 键 词： | 罗格列酮 纤溶酶原激活物抑制物1 2型糖尿病 |
Role of rosiglitazone in blood lipids and plasma PAI-1 activity in type 2 diabetic patients |
| |
| Hu Gui-fang,Wu Ge,Yang Lu. Role of rosiglitazone in blood lipids and plasma PAI-1 activity in type 2 diabetic patients[J]. Journal of Guangdong Medical College, 2008, 26(3) |
| |
| Authors: | Hu Gui-fang Wu Ge Yang Lu |
| |
| Abstract: | Objective To investigate the influence of rosiglitazone on blood lipids and plasma PAI-1 activity in type 2 diabetic patients.Methods Sixty patients with type 2 diabetes were randomly divided into rosiglitazone group and control group,and then fasting blood glucose,blood lipids and plasma PAI-1 activity in both groups were determined in all patients before and 12 weeks after treatment. Results Compared with control group,serum triglyceride content and plasma PAI1 activity decreased,but serum HDL-L level increased in rosiglitazone group after 12-week treatment(P<0.05).Conclusion Rosiglitazone can improve the metabolic disturbance and downregulate PAI-1 activity in type 2 diabetic patients,which is helpful in the improvement or delay of atherosclerosis development. |
| |
| Keywords: | rosiglitazone PAI-1 type 2 diabetes mellitus |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
